Adamas Completes Acquisition of OSMOLEX ER®

(January 5, 2021) – Adamas completed acquisition of OSMOLEX ER® via a settlement of patent litigation with Osmotica Pharmeceuticals US LLC. OSMOLEX ER® is an FDA-approved, extended-release tablet for the treatment of Parkinson’s disease. Click here to learn more about Adamas and OSMOLEX ER®.

Contact UsTerms Of UsePrivacy Policy

The Parkinson Alliance is a nonprofit, tax-exempt charitable organization under section 501(c)(3) of the Internal Revenue Code. Donations are tax-deductible as allowed by law. Copyright © 2022 The Parkinson Alliance. All rights reserved.